XML 123 R77.htm IDEA: XBRL DOCUMENT v3.24.0.1

Restructuring costs and similar items (Tables)

12 Months Ended

Dec. 31, 2023

Analysis of income and expense [abstract]

Summary of Restructuring Costs and Similar Items

Restructuring costs and similar items amounted to €1,490 million in 2023, €1,336 million in 2022 and €820 million in 2021, and were comprised of the following items:

(€ million)			2023			2022						2021
Employee-related expenses			489			507						193
Charges, gains or losses on assets(a)			293			261						110
Costs related to transformation programs			676			547						463
Other			32			21						54
Total			1,490			1,336						820

(a)    This line consists of impairment losses and accelerated depreciation charges related to site closures (including leased sites), and gains or losses on divestments of assets arising from reorganization decisions made by Sanofi.

X

- References

No definition available.

+ Details

Name:	ifrs-full_AnalysisOfIncomeAndExpenseAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of restructuring costs details.

+ References

No definition available.

+ Details

Name:	sny_DisclosureOfRestructuringCostsDetailsTableTextBlock
Namespace Prefix:	sny_
Data Type:	dtr-types1:textBlockItemType
Balance Type:	na
Period Type:	duration